Efficacy of paraspinal anesthetic block in @entity1 with chronic XXXX refractory to drug therapy: a randomized clinical trial.

@entity1 @entity1425 @entity3825 @entity2371 @entity3303 @entity158 @entity616
PURPOSE: To determine whether @entity616 reduces @entity158 scores compared to placebo in @entity1 with chronic @entity2371 refractory to drug therapy. METHODS: Subjects with chronic @entity2371 due to benign conditions and refractory to drug therapy were invited to participate in a randomized, double blind, superiority trial at a tertiary reference center. Subjects were randomly allocated to receive paraspinal anesthetic block with 1% @entity3303 without @entity1425 or placebo (control). @entity3303 was injected along the spinal process of the @entity158 segment in the supra- and interspinal ligaments using a 25G X 2" needle. Placebo consisted of introduction of the needle in the same segment without injecting any substance. The main outcome measured was the @entity158 score based on a visual analog scale at T0 (baseline), T1 (within 15 min after the procedure) and T2 (one week after the procedure). Data were statistically analyzed by ANOVA and the 95% confidence interval (95%CI). RESULTS: Mean age was similar for both groups, i.e., 51.2 (paraspinal anesthetic block) and 51.8 years (control). A blind examiner measured the degree of @entity158 according to the visual analog scale from 0 (no @entity158 ) to 10 ( @entity158 imaginable). Based on the visual analog scale, the mean @entity158 scores of the paraspinal anesthetic block group at T0, T1 and T2 were 5.50 (SD=2.92; 95%CI 3.84-7.15), 2.72 (SD=2.10; 95%CI 1.53-3.90), and 4.36 (SD=2.37; 95%CI 1.89-6.82), respectively. The difference between T0 and T1 was statistically significant, with p=0.03. CONCLUSIONS: Paraspinal anesthetic block had a small effect on visual analog scale @entity158 score immediately after the injections, but no sustained benefit after one week. Further studies are needed to determine the efficacy of paraspinal anesthetic block with different @entity3303 doses for the treatment of @entity3825 of other causes.
